

## **Neurosensory deficits and functional outcomes in childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS)**

Chiara Papini, PhD, MPH<sup>1\*</sup>, Pinki Prasad, MD, MPH<sup>\*2</sup>, Mengqi Xing MR<sup>3</sup>, Sedigheh Mirzaei PhD<sup>3</sup>, Emily Tonorezos, MD MPH<sup>4</sup>, David R. Freyer, DO, MS<sup>5</sup>, Christopher Weldon, MD, PhD<sup>6</sup>, Austin L. Brown, PhD, MPH<sup>7</sup>, Eric J. Chow, MD, MPH<sup>8,9</sup>, Rebecca M. Howell, PhD<sup>10</sup>, AnnaLynn M. Williams, PhD<sup>11</sup>, Kirsten K. Ness, PhD<sup>12</sup>, Deokumar Srivastava, PhD<sup>13</sup>, Vikki G. Nolan, DSc, MPH<sup>12</sup>, Gregory T. Armstrong, MD, MSCE<sup>12</sup>, Kevin R. Krull, PhD<sup>1</sup>, Robert J. Hayashi, MD<sup>14#</sup>, Tara M. Brinkman, PhD<sup>1,12#</sup>

<sup>1</sup> Department of Psychology and Biobehavioral Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA

<sup>2</sup> Manning Family Children's, Department of Pediatrics, Division of Pediatric Hematology Oncology, Louisiana State University Health Sciences Center/Children's Hospital of New Orleans, New Orleans, LA, USA

<sup>3</sup> Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA

<sup>4</sup> Weill Cornell Medical College, New York, NY, USA

<sup>5</sup> Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA

<sup>6</sup> Department of Surgery, Boston Children's Hospital, Boston, MA, USA

<sup>7</sup> Department of Pediatrics, Section of Hematology/Oncology, Baylor College of Medicine, Houston, TX, USA

<sup>8</sup> Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA

<sup>9</sup> Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA

<sup>10</sup> Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

<sup>11</sup> Department of Surgery, Division of Supportive Care in Cancer, University of Rochester Medical Center, Rochester, NY, USA

<sup>12</sup> Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA

<sup>13</sup> Division of Pediatric Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA

\* Chiara Papini and Pinki Prasad should be considered co-first authors.

# Tara M. Brinkman and Robert J. Hayashi should be considered co-senior authors.

## **Neurosensory deficits and functional outcomes in childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS)**

**Background:** Survivors of childhood cancer are at risk for neurosensory deficits secondary to their disease and treatment. Previous research has characterized system-specific (e.g., visual) impairments; however, the prevalence of multisystem neurosensory deficits and their functional impact remain unknown.

**Methods:** Adult 5-year survivors (n=20037, median age 36 [range 18-69] years, 53.4% male) and sibling controls (n=4121) reported neurosensory deficits related to vision, hearing, vestibular, and neuropathy. Comorbidities were graded using modified CTCAE v5 and defined as having at least one grade 1 neurosensory deficit in one, two, and three/four systems.

Survivors reported neurocognitive function (CCSS Neurocognitive questionnaire; impairment: <10<sup>th</sup> %ile of sibling distribution), emotional distress (BSI-18; impairment: T score ≥63), quality of life (SF-36; impairment: T score <40), and functional independence. Multivariable models estimated the prevalence of neurosensory comorbidities, adjusted for age, sex, and race.

Multivariable models further adjusted for other chronic conditions and neurotoxic therapies examined associations between comorbidities and functional outcomes in survivors.

**Results:** Survivors had higher prevalence of neurosensory deficits in one (31% vs. 24%; prevalence ratio [PR] 1.4, 95% confidence interval [CI] 1.3-1.5), two (14% vs. 8%; 2.2, 1.9-2.5) and three/four systems (9% vs. 3%; 3.3, 2.9-4.1) than siblings. Neurosensory comorbidities were associated with greater risk of neurocognitive impairment (task efficiency and memory), emotional distress (anxiety) and poor quality of life (physical and social function) in a dose-dependent manner in survivors (Table). Similar effects were observed for indicators of functional independence: assistance with personal care/routine needs (one system: relative risk [RR] 2.7, 95% CI 2.2-3.3; two systems: 4.1, 3.3-5.0; three/four systems: 6.5, 5.4-7.9), interference with job/school (2.5, 2.2-3.0; 3.8, 3.2-4.5; 6.1, 5.2-7.1), no driver's license (1.5, 1.3-1.8; 2.4, 2.1-2.8; 3.8, 3.2-4.4), and non-independent living (1.3, 1.2-1.4; 1.8, 1.6-2.0; 2.1, 1.9-2.4).

**Conclusions:** Adult survivors of childhood cancer have high rates of comorbid neurosensory deficits that have a dose-dependent impact on functional outcomes. Survivors with multisystem deficits should be prioritized for interventions to support functional independence.

**Table.** Relative risk (95% CI) of impaired outcomes in survivors with neurosensory comorbidities

| <b>Neurosensory<br/>comorbidities<br/>(# organ systems)</b> | <b>Memory</b> | <b>Task<br/>Efficiency</b> | <b>Anxiety</b> | <b>Physical<br/>Function</b> | <b>Social<br/>Function</b> |
|-------------------------------------------------------------|---------------|----------------------------|----------------|------------------------------|----------------------------|
| 0 (ref.)                                                    | -             | -                          | -              | -                            | -                          |
| 1                                                           | 1.6 (1.4-1.8) | 1.8 (1.6-2.0)              | 2.6 (2.2-3.1)  | 2.2 (1.9-2.6)                | 1.9 (1.7-2.1)              |
| 2                                                           | 2.2 (2.0-2.5) | 2.4 (2.2-2.7)              | 3.4 (2.8-4.1)  | 3.1 (2.7-3.5)                | 2.5 (2.2-2.8)              |
| 3/4                                                         | 3.1 (2.7-3.4) | 3.3 (3.0-3.7)              | 5.2 (4.4-6.3)  | 4.4 (3.8-5.0)                | 3.2 (2.9-3.7)              |

*Characters (no spaces) including title, body, and table: 2,596 / 2,600*